Maxvax has begun construction on a large scale GMP production facility located in Lingang District of Shanghai with boasting over 129,000 square feet capable of producing 100 million vaccine doses a year. The facility will be capable of engineering recombinant bacteria cell protein vaccines and live attenuated vaccines and is expected to be operational in Q3, 2024.